# EDGAR Filing Document

**Accession Number:** 0001611024
**File Stem:** 0001193125-23-035920
**Filing Date:** 2023-2
**Character Count:** 18256
**Document Hash:** 4fb14d4b7504a33207be1a3ec449eac5
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-23-035920.hdr.sgml**: 20230213

**ACCESSION NUMBER**: 0001193125-23-035920

**CONFORMED SUBMISSION TYPE**: SC 13G

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20230213

**DATE AS OF CHANGE**: 20230213

**GROUP MEMBERS**: CHANG 2006 FAMILY TRUST

**GROUP MEMBERS**: JEC 2019 TRUST

**GROUP MEMBERS**: RTC 2019 TRUST

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Allogene Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001737287
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 823562771
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC 13G
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-90685
- **FILM NUMBER:** 23619058

**BUSINESS ADDRESS:**
- **STREET 1:** 210 EAST GRAND AVENUE
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
- **BUSINESS PHONE:** (650) 457-2700

**MAIL ADDRESS:**
- **STREET 1:** 210 EAST GRAND AVENUE
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Chang David D
- **CENTRAL INDEX KEY:** 0001611024

**FILING VALUES:**
- **FORM TYPE:** SC 13G

**MAIL ADDRESS:**
- **STREET 1:** C/O ALLOGENE THERAPEUTICS, INC.
- **STREET 2:** 210 EAST GRAND AVENUE
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080

------

------

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

------

**SCHEDULE 13G** 

**Under the Securities Exchange Act of 1934** 

**(Amendment No. __)** 

------

## ALLOGENE THERAPEUTICS, INC.
**(Name of Issuer)** 

**Common Stock** 

**(Title of Class of Securities)** 

**019770 10 6** 

**(CUSIP Number)** 

**December 31, 2022** 

**(Date of Event Which Requires Filing of this Statement)** 

------

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☐ Rule 13d-1(c)

☒ Rule 13d-1(d)

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

------

---

| | | |
|:---|:---|:---|
| **CUSIP No. 019770 10 6** | **13G** | **Page 2 of 10 Pages** |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp; 1 | &nbsp;&nbsp;&nbsp;&nbsp;Names of Reporting Persons<br>&nbsp;&nbsp;&nbsp;&nbsp;David Chang, M.D., Ph.D. |
| &nbsp;&nbsp;&nbsp; 2 | &nbsp;&nbsp;&nbsp;&nbsp;Check the Appropriate Box if a Member of a Group<br>&nbsp;&nbsp;&nbsp;&nbsp;(a) ☐ (b) ☐ |
| &nbsp;&nbsp;&nbsp; 3 | &nbsp;&nbsp;&nbsp;&nbsp;SEC Use Only |
| &nbsp;&nbsp;&nbsp; 4 | &nbsp;&nbsp;&nbsp;&nbsp;Citizenship or Place of Organization<br>&nbsp;&nbsp;&nbsp;&nbsp;United States of America and Israel |

---

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;&nbsp; Number of<br> Shares<br> Beneficially <br> Owned by<br> Each<br> Reporting<br> Person<br> With: | 5 | &nbsp;&nbsp;&nbsp;&nbsp;Sole Voting Power<br>&nbsp;&nbsp;&nbsp;&nbsp;5,514,436 Shares (1) |
| &nbsp;&nbsp;&nbsp; Number of<br> Shares<br> Beneficially <br> Owned by<br> Each<br> Reporting<br> Person<br> With: | 6 | &nbsp;&nbsp;&nbsp;&nbsp;Shared Voting Power<br>&nbsp;&nbsp;&nbsp;&nbsp;2,913,196 Shares (2) |
| &nbsp;&nbsp;&nbsp; Number of<br> Shares<br> Beneficially <br> Owned by<br> Each<br> Reporting<br> Person<br> With: | 7 | &nbsp;&nbsp;&nbsp;&nbsp;Sole Dispositive Power<br>&nbsp;&nbsp;&nbsp;&nbsp;5,514,436 Shares (1) |
| &nbsp;&nbsp;&nbsp; Number of<br> Shares<br> Beneficially <br> Owned by<br> Each<br> Reporting<br> Person<br> With: | 8 | &nbsp;&nbsp;&nbsp;&nbsp;Shared Dispositive Power<br>&nbsp;&nbsp;&nbsp;&nbsp;2,913,196 Shares (2) |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp; 9 | &nbsp;&nbsp;&nbsp;&nbsp;Aggregate Amount Beneficially Owned by Each Reporting Person<br>&nbsp;&nbsp;&nbsp;&nbsp;8,427,632 Shares |
| &nbsp;&nbsp;&nbsp;10 | &nbsp;&nbsp;&nbsp;&nbsp;Check if the Aggregate Amount in Row (9) Excludes Certain Shares<br>&nbsp;&nbsp;&nbsp;&nbsp;☐ |
| &nbsp;&nbsp;&nbsp;11 | &nbsp;&nbsp;&nbsp;&nbsp;Percent of Class Represented by Amount in Row (9)<br>&nbsp;&nbsp;&nbsp;&nbsp;5.7% (3) |
| &nbsp;&nbsp;&nbsp;12 | &nbsp;&nbsp;&nbsp;&nbsp;Type of Reporting Person<br>&nbsp;&nbsp;&nbsp;&nbsp;IN |

---

(1) Includes 3,328,238 shares of common stock issuable within 60 days of December 31, 2022 upon the exercise
of stock options held by the Reporting Person and 149,863 shares issuable upon the settlement of Restricted Stock Units held by the Reporting Person that are releasable within 60 days of December 31, 2022.

(2) Includes (a) 1,201,108 shares of common stock beneficially owned by the Chang 2006 Family Trust, of which
Dr. Chang is co-trustee, (b) 856,044 shares of common stock beneficially owned by the JEC 2019 Trust, of which Dr. Chang is co-trustee and (c) 856,044
shares of common stock beneficially owned by the RTC 2019 Trust, of which Dr. Chang is co-trustee.

(3) This percentage is calculated based on 144,210,154 shares of common stock outstanding as of October 31,
2022, as reported in the Issuer's Quarterly Report on Form 10-Q filed on November 2, 2022.

------

---

| | | |
|:---|:---|:---|
| **CUSIP No. 019770 10 6** | **13G** | **Page 3 of 10 Pages** |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp; 1 | &nbsp;&nbsp;&nbsp;&nbsp;Names of Reporting Persons<br>&nbsp;&nbsp;&nbsp;&nbsp;Chang 2006 Family Trust |
| &nbsp;&nbsp;&nbsp; 2 | &nbsp;&nbsp;&nbsp;&nbsp;Check the Appropriate Box if a Member of a Group<br>&nbsp;&nbsp;&nbsp;&nbsp;(a) ☐ (b) ☐ |
| &nbsp;&nbsp;&nbsp; 3 | &nbsp;&nbsp;&nbsp;&nbsp;SEC Use Only |
| &nbsp;&nbsp;&nbsp; 4 | &nbsp;&nbsp;&nbsp;&nbsp;Citizenship or Place of Organization<br>&nbsp;&nbsp;&nbsp;&nbsp;Delaware |

---

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;&nbsp; Number of<br> Shares<br> Beneficially <br> Owned by<br> Each<br> Reporting<br> Person<br> With: | 5 | &nbsp;&nbsp;&nbsp;&nbsp;Sole Voting Power<br>&nbsp;&nbsp;&nbsp;&nbsp;0 Shares |
| &nbsp;&nbsp;&nbsp; Number of<br> Shares<br> Beneficially <br> Owned by<br> Each<br> Reporting<br> Person<br> With: | 6 | &nbsp;&nbsp;&nbsp;&nbsp;Shared Voting Power<br>&nbsp;&nbsp;&nbsp;&nbsp;1,201,108 Shares |
| &nbsp;&nbsp;&nbsp; Number of<br> Shares<br> Beneficially <br> Owned by<br> Each<br> Reporting<br> Person<br> With: | 7 | &nbsp;&nbsp;&nbsp;&nbsp;Sole Dispositive Power<br>&nbsp;&nbsp;&nbsp;&nbsp;0 Shares |
| &nbsp;&nbsp;&nbsp; Number of<br> Shares<br> Beneficially <br> Owned by<br> Each<br> Reporting<br> Person<br> With: | 8 | &nbsp;&nbsp;&nbsp;&nbsp;Shared Dispositive Power<br>&nbsp;&nbsp;&nbsp;&nbsp;1,201,108 Shares |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp; 9 | &nbsp;&nbsp;&nbsp;&nbsp;Aggregate Amount Beneficially Owned by Each Reporting Person<br>&nbsp;&nbsp;&nbsp;&nbsp;1,201,108 Shares |
| &nbsp;&nbsp;&nbsp;10 | &nbsp;&nbsp;&nbsp;&nbsp;Check if the Aggregate Amount in Row (9) Excludes Certain Shares<br>&nbsp;&nbsp;&nbsp;&nbsp;☐ |
| &nbsp;&nbsp;&nbsp;11 | &nbsp;&nbsp;&nbsp;&nbsp;Percent of Class Represented by Amount in Row (9)<br>&nbsp;&nbsp;&nbsp;&nbsp;0.8% (1) |
| &nbsp;&nbsp;&nbsp;12 | &nbsp;&nbsp;&nbsp;&nbsp;Type of Reporting Person<br>&nbsp;&nbsp;&nbsp;&nbsp;OO |

---

(1) This percentage is calculated based on 144,210,154 shares of common stock outstanding as of October 31,
2022, as reported in the Issuer's Quarterly Report on Form 10-Q filed on November 2, 2022.

------

---

| | | |
|:---|:---|:---|
| **CUSIP No. 019770 10 6** | **13G** | **Page 4 of 10 Pages** |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp; 1 | &nbsp;&nbsp;&nbsp;&nbsp;Names of Reporting Persons<br>&nbsp;&nbsp;&nbsp;&nbsp;JEC 2019 Trust |
| &nbsp;&nbsp;&nbsp; 2 | &nbsp;&nbsp;&nbsp;&nbsp;Check the Appropriate Box if a Member of a Group<br>&nbsp;&nbsp;&nbsp;&nbsp;(a) ☐ (b) ☐ |
| &nbsp;&nbsp;&nbsp; 3 | &nbsp;&nbsp;&nbsp;&nbsp;SEC Use Only |
| &nbsp;&nbsp;&nbsp; 4 | &nbsp;&nbsp;&nbsp;&nbsp;Citizenship or Place of Organization<br>&nbsp;&nbsp;&nbsp;&nbsp;California |

---

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;&nbsp; Number of<br> Shares<br> Beneficially <br> Owned by<br> Each<br> Reporting<br> Person<br> With: | 5 | &nbsp;&nbsp;&nbsp;&nbsp;Sole Voting Power<br>&nbsp;&nbsp;&nbsp;&nbsp;0 Shares |
| &nbsp;&nbsp;&nbsp; Number of<br> Shares<br> Beneficially <br> Owned by<br> Each<br> Reporting<br> Person<br> With: | 6 | &nbsp;&nbsp;&nbsp;&nbsp;Shared Voting Power<br>&nbsp;&nbsp;&nbsp;&nbsp;856,044 Shares |
| &nbsp;&nbsp;&nbsp; Number of<br> Shares<br> Beneficially <br> Owned by<br> Each<br> Reporting<br> Person<br> With: | 7 | &nbsp;&nbsp;&nbsp;&nbsp;Sole Dispositive Power<br>&nbsp;&nbsp;&nbsp;&nbsp;0 Shares |
| &nbsp;&nbsp;&nbsp; Number of<br> Shares<br> Beneficially <br> Owned by<br> Each<br> Reporting<br> Person<br> With: | 8 | &nbsp;&nbsp;&nbsp;&nbsp;Shared Dispositive Power<br>&nbsp;&nbsp;&nbsp;&nbsp;856,044 Shares |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp; 9 | &nbsp;&nbsp;&nbsp;&nbsp;Aggregate Amount Beneficially Owned by Each Reporting Person<br>&nbsp;&nbsp;&nbsp;&nbsp;856,044 Shares |
| &nbsp;&nbsp;&nbsp;10 | &nbsp;&nbsp;&nbsp;&nbsp;Check if the Aggregate Amount in Row (9) Excludes Certain Shares<br>&nbsp;&nbsp;&nbsp;&nbsp;☐ |
| &nbsp;&nbsp;&nbsp;11 | &nbsp;&nbsp;&nbsp;&nbsp;Percent of Class Represented by Amount in Row (9)<br>&nbsp;&nbsp;&nbsp;&nbsp;0.6% (1) |
| &nbsp;&nbsp;&nbsp;12 | &nbsp;&nbsp;&nbsp;&nbsp;Type of Reporting Person<br>&nbsp;&nbsp;&nbsp;&nbsp;OO |

---

(1) This percentage is calculated based on 144,210,154 shares of common stock outstanding as of October 31,
2022, as reported in the Issuer's Quarterly Report on Form 10-Q filed on November 2, 2022.

------

---

| | | |
|:---|:---|:---|
| **CUSIP No. 019770 10 6** | **13G** | **Page 5 of 10 Pages** |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp; 1 | &nbsp;&nbsp;&nbsp;&nbsp;Names of Reporting Persons<br>&nbsp;&nbsp;&nbsp;&nbsp;RTC 2019 Trust |
| &nbsp;&nbsp;&nbsp; 2 | &nbsp;&nbsp;&nbsp;&nbsp;Check the Appropriate Box if a Member of a Group<br>&nbsp;&nbsp;&nbsp;&nbsp;(a) ☐ (b) ☐ |
| &nbsp;&nbsp;&nbsp; 3 | &nbsp;&nbsp;&nbsp;&nbsp;SEC Use Only |
| &nbsp;&nbsp;&nbsp; 4 | &nbsp;&nbsp;&nbsp;&nbsp;Citizenship or Place of Organization<br>&nbsp;&nbsp;&nbsp;&nbsp;California |

---

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;&nbsp; Number of<br> Shares<br> Beneficially <br> Owned by<br> Each<br> Reporting<br> Person<br> With: | 5 | &nbsp;&nbsp;&nbsp;&nbsp;Sole Voting Power<br>&nbsp;&nbsp;&nbsp;&nbsp;0 Shares |
| &nbsp;&nbsp;&nbsp; Number of<br> Shares<br> Beneficially <br> Owned by<br> Each<br> Reporting<br> Person<br> With: | 6 | &nbsp;&nbsp;&nbsp;&nbsp;Shared Voting Power<br>&nbsp;&nbsp;&nbsp;&nbsp;856,044 Shares |
| &nbsp;&nbsp;&nbsp; Number of<br> Shares<br> Beneficially <br> Owned by<br> Each<br> Reporting<br> Person<br> With: | 7 | &nbsp;&nbsp;&nbsp;&nbsp;Sole Dispositive Power<br>&nbsp;&nbsp;&nbsp;&nbsp;0 Shares |
| &nbsp;&nbsp;&nbsp; Number of<br> Shares<br> Beneficially <br> Owned by<br> Each<br> Reporting<br> Person<br> With: | 8 | &nbsp;&nbsp;&nbsp;&nbsp;Shared Dispositive Power<br>&nbsp;&nbsp;&nbsp;&nbsp;856,044 Shares |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp; 9 | &nbsp;&nbsp;&nbsp;&nbsp;Aggregate Amount Beneficially Owned by Each Reporting Person<br>&nbsp;&nbsp;&nbsp;&nbsp;856,044 Shares |
| &nbsp;&nbsp;&nbsp;10 | &nbsp;&nbsp;&nbsp;&nbsp;Check if the Aggregate Amount in Row (9) Excludes Certain Shares<br>&nbsp;&nbsp;&nbsp;&nbsp;☐ |
| &nbsp;&nbsp;&nbsp;11 | &nbsp;&nbsp;&nbsp;&nbsp;Percent of Class Represented by Amount in Row (9)<br>&nbsp;&nbsp;&nbsp;&nbsp;0.6% (1) |
| &nbsp;&nbsp;&nbsp;12 | &nbsp;&nbsp;&nbsp;&nbsp;Type of Reporting Person<br>&nbsp;&nbsp;&nbsp;&nbsp;OO |

---

(1) This percentage is calculated based on 144,210,154 shares of common stock outstanding as of October 31,
2022, as reported in the Issuer's Quarterly Report on Form 10-Q filed on November 2, 2022.

------

---

| | | |
|:---|:---|:---|
| **CUSIP No. 019770 10 6** | **13G** | **Page 6 of 10 Pages** |

---

---

| | |
|:---|:---|
| **Item 1(a).** | Name of Issuer:<br>Allogene Therapeutics, Inc. |
| **Item 1(b).** | Address of Issuer's Principal Executive Offices:<br>210 East Grand Avenue<br> South San Francisco, CA 94080 |
| **Item 2(a).** | Names of Persons Filing:<br>David Chang, M.D., Ph.D.<br> Chang 2006 Family Trust<br> JEC 2019 Trust<br> RTC 2019 Trust |
| **Item 2(b).** | Address of Principal Business Office, or, if none, Residence:<br>The address of David Chang, M.D., Ph.D. is:<br> 1755 Ocean Avenue, #803, Santa Monica, CA 90401<br>The address of Chang 2006 Family Trust, JEC 2019 Trust and RTC 2019 Trust is:<br> 1755 Ocean Avenue, #803, Santa Monica, CA 90401 |
| **Item 2(c).** | Citizenship:<br>David Chang: USA<br> Chang 2006 Family Trust: California<br> JEC 2019 Trust: California<br> RTC 2019 Trust: California |
| **Item 2(d).** | Title of Class of Securities:<br>Common Stock |
| **Item 2(e).** | CUSIP No.:<br>019770 10 6 |
| **Item 3.** | Not Applicable. |

---

------

---

| | | |
|:---|:---|:---|
| **CUSIP No. 019770 10 6** | **13G** | **Page 7 of 10 Pages** |

---

**Item 4.** **Ownership** <br>

The information requested hereinafter is set forth in items 5 through 9 and 11 of the cover page to this Schedule 13G. Ownership is stated as of December 31, 2022. This percentage is calculated based on 144,210,154 shares of common stock outstanding as of October 31, 2022, as reported in the Issuer's Quarterly Report on Form 10-Q filed on November 2, 2022.

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Reporting Person** | **Shares Held**<br>**Directly** | **Sole**<br>**Voting**<br>**Power** | **Shared**<br>**Voting**<br>**Power** | **Sole**<br>**Dispositive**<br>**Power** | **Shared**<br>**Dispositive**<br>**Power** | **Beneficial**<br>**Ownership** | **Percentage**<br>**of Class(1)** |
|  David Chang, M.D. Ph.D. | 5514436 | 5514436 | 2913196 | 5514436 | 2913196 | 8427632 | 3.8% |
|  Chang 2006 Family Trust | 1201108 | 0 | 1201108 | 0 | 1201108 | 1201108 | 0.8% |
|  JEC 2019 Trust | 856044 | 0 | 856044 | 0 | 856044 | 856044 | 0.6% |
|  RTC 2019 Trust | 856044 | 0 | 856044 | 0 | 856044 | 856044 | 0.6% |

---

(1) This percentage is calculated based on 144,210,154 shares of common stock outstanding as of October 31,
2022, as reported in the Issuer's Quarterly Report on Form 10-Q filed on November 2, 2022.

**Item 5.** **Ownership of Five Percent or Less of a Class.** <br>

If this statement is being filed to report the fact that as of the date hereof, the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ☐

**Item 6.** **Ownership of More than Five Percent on Behalf of Another Person** <br>

Not applicable

**Item 7.** **Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person** <br>

Not applicable

**Item 8.** **Identification and Classification of Members of the Group** <br>

Not applicable

**Item 9.** **Notice of Dissolution of Group** <br>

Not applicable

------

---

| | | |
|:---|:---|:---|
| **CUSIP No. 019770 10 6** | **13G** | **Page 8 of 10 Pages** |

---

**Item 10.** **Certifications** <br>

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

------

---

| | | |
|:---|:---|:---|
| **CUSIP No. 019770 10 6** | **13G** | **Page 9 of 10 Pages** |

---

**SIGNATURE** 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 10, 2023

---

| | |
|:---|:---|
| /s/ David Chang | /s/ David Chang |
| **David Chang, M.D., Ph.D.** | **David Chang, M.D., Ph.D.** |
| **Chang 6006 Family Trust** | **Chang 6006 Family Trust** |
| By: | /s/ David Chang |
| Name: | David Chang, Co-Trustee |
| **JEC 2019 Trust** | **JEC 2019 Trust** |
| By: | /s/ David Chang |
| Name: | David Chang, Co-Trustee |
| **RTC 2019 Trust** | **RTC 2019 Trust** |
| By: | /s/ David Chang |
| Name: | David Chang, Co-Trustee |

---

## Exhibit 99.1

---

| | | |
|:---|:---|:---|
| **CUSIP No. 019770 10 6** | **13G** | **Page 10 of 10 Pages** |

---

**Exhibit 99.1** 

JOINT FILING AGREEMENT

In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with all other Reporting Persons (as such term is defined in the Schedule 13G referred to below) on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the common stock of Allogene Therapeutics, Inc., a Delaware corporation, and that this Agreement may be included as an Exhibit to such joint filing. This Agreement may be executed in any number of counterparts all of which, taken together, shall constitute one and the same instrument.

Dated: February 10, 2023

---

| | |
|:---|:---|
| /s/ David Chang | /s/ David Chang |
| **David Chang, M.D., Ph.D.** | **David Chang, M.D., Ph.D.** |
| **Chang 2006 Family Trust** | **Chang 2006 Family Trust** |
| By: | /s/ David Chang |
| Name: | David Chang, Co-Trustee |
| **JEC 2019 Trust** | **JEC 2019 Trust** |
| By: | /s/ David Chang |
|  | David Chang, Co-Trustee |
| **RTC 2019 Trust** | **RTC 2019 Trust** |
| By: | /s/ David Chang |
| Name: | David Chang, Co-Trustee |

---